Vulvar cancer as a target for molecular medicine

Front Biosci (Schol Ed). 2011 Jan 1;3(1):136-44. doi: 10.2741/s139.

Abstract

Vulvar carcinoma is a rare female genital neoplasm. Although numerous molecular defects in vulvar carcinomas have been reported until now, no molecular markers that could be applied in daily clinical work have been identified so far. However, there is emerging evidence that specific mutations and gene expression patterns may be used as diagnostic tools in oncology. In this article we systematically review genetic alterations that may contribute to the development and progression of vulvar carcinoma. We conclude by suggesting molecular markers of potential clinical value in the diagnostics of this type of cancer.

Publication types

  • Review

MeSH terms

  • 14-3-3 Proteins / genetics
  • 14-3-3 Proteins / metabolism
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Carcinoma / epidemiology
  • Carcinoma / genetics*
  • Carcinoma / physiopathology*
  • Carcinoma / virology
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21 / genetics
  • Cyclins / metabolism
  • Exonucleases / genetics
  • Exonucleases / metabolism
  • Exoribonucleases
  • Female
  • Genes, p53 / genetics
  • Human papillomavirus 16*
  • Humans
  • Matrix Metalloproteinases / metabolism
  • Papillomavirus Infections / physiopathology*
  • Point Mutation / genetics
  • Precancerous Conditions / physiopathology*
  • Vulvar Neoplasms / epidemiology
  • Vulvar Neoplasms / genetics*
  • Vulvar Neoplasms / physiopathology*
  • Vulvar Neoplasms / virology

Substances

  • 14-3-3 Proteins
  • Biomarkers, Tumor
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Exonucleases
  • Exoribonucleases
  • SFN protein, human
  • Matrix Metalloproteinases